• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button Iconabbvie

abbvie

Page 2 of 3
AbbVie Allergan deal
HealthWhat AbbVie’s $63 Billion Deal to Buy Allergan Says About the Drug Industry
By Sy MukherjeeJune 25, 2019
Pharmaceutical Executives Testify At Senate Finance Committee Hearing On Drug Prices
HealthSenator Calls Tying Drugmaker CEO Pay to High Drug Price ‘Problematic’
By Erik ShermanFebruary 27, 2019
Hepatitis C drug can cure, if patients can get it
HealthHepatitis C Drugs Can Cost $84,000. This New One May Be Just As Good—But Cost $300
By Sy MukherjeeApril 12, 2018
BioGen Alzheimers
HealthCould a New Immunotherapy Medical Approach Break the Alzheimer’s Drug Curse?
By Sy MukherjeeOctober 24, 2017
Hepatitis C drug can cure, if patients can get it
HealthThe FDA Just Approved the First Drug That Can Treat All Hepatitis C Strains in Just 8 Weeks
By Sy MukherjeeAugust 3, 2017
CA: Companies In California
HealthThe World’s Best-Selling Drug Just Lost a Key Patent Battle
By Sy MukherjeeMay 18, 2017
The Davos World Economic Forum 2015
HealthNovartis Just Got Some Great News in Its Battle for Amgen’s Market Share
By Sy MukherjeeAugust 31, 2016
George Scangos, CEO of Biogen Inc. speaks during Reuters Health Summit in New York
HealthBiogen Shares Are Spiking On Rumors of a Mega-Deal With Its Rivals
By Sy MukherjeeAugust 2, 2016
Close up of surgical tools and money
HealthTwo of the World’s Best-Selling Drugs Are Headed for a Lot More Competition
By Sy MukherjeeJuly 15, 2016
Drugs From European Pharmaceuticals Companies As Stocks Outperformed The Stoxx 600 Index By 1.2 percentage Points
FinanceBiotech Stocks Are Down 25% So Far This Year
By Sy MukherjeeMay 6, 2016
A screen displays the share price for pharmaceutical maker AbbVie on the floor of the New York Stock Exchange
HealthSamsung’s Drug Group Is Taking AbbVie to Court in Biotech Copycat Push
By ReutersApril 4, 2016
519891667
HealthDrug companies are paying huge sums to fast-track FDA approval
By Laura LorenzettiOctober 20, 2015
Fight against Daesh in Turkey's Syrian borderline
FeaturesISIS and drug sales — 5 things to know today
By Tom Huddleston Jr. and Geoffrey SmithJuly 24, 2015
FinanceIreland’s Horizon Pharma launches hostile, $3 billion bid for U.S. rival
By Tom Huddleston Jr.July 7, 2015
IL: Corporations In Illinois
FinanceAbbVie to buy cancer drug maker Pharmacyclics in $21 billion deal
By ReutersMarch 4, 2015
1
  • 1
  • 2
  • 3
3
Most Popular
Success
Japanese companies are paying older workers to sit by a window and do nothing—while Western CEOs demand super-AI productivity just to keep your jobAn image of a popular article
By Orianna Rosa RoyleFebruary 27, 2026
Middle East
Iran is now on 'death ground' amid existential threat from U.S. attacks and could 'go big' in retaliation, former NATO commander warnsAn image of a popular article
By Jason MaFebruary 28, 2026
AI
The week the AI scare turned real and America realized maybe it isn't ready for what's comingAn image of a popular article
By Nick LichtenbergFebruary 28, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
Fortune Secondary Logo
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.